![Klaas Poelstra](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Klaas Poelstra
Corporate Officer/Principal presso University of Groningen
Posizioni attive di Klaas Poelstra
Società | Posizione | Inizio | Fine |
---|---|---|---|
University of Groningen | Corporate Officer/Principal | 21/08/2009 | - |
Storia della carriera di Klaas Poelstra
Precedenti posizioni note di Klaas Poelstra
Società | Posizione | Inizio | Fine |
---|---|---|---|
BiOrion Technologies BV
![]() BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Direttore Tecnico/Scientifico/R&S | 01/01/2003 | - |
Fondatore | 21/08/2009 | - |
Statistiche
Distribuzione geografica
Paesi Bassi | 3 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
BiOrion Technologies BV
![]() BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Klaas Poelstra
- Esperienza